About NEUROPHET
NEUROPHET is a company based in Seoul (South Korea) founded in 2016 by Donghyeon Kim and Junkil Been.. NEUROPHET has raised $24.4 million across 4 funding rounds from investors including Shinhan Bank, SBI Investment Korea and Samjin Pharm. NEUROPHET operates in a competitive market with competitors including Viz.ai, icometrix, RapidAI, Jvion and BrainSightAI, among others.
- Headquarter Seoul, South Korea
- Founders Donghyeon Kim, Junkil Been
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Neurophet, Inc.
-
Annual Revenue
$1.51 M (USD)41.86as on Dec 31, 2024
-
Net Profit
$-10.24 M (USD)-386.93as on Dec 31, 2024
-
EBITDA
$-9.19 M (USD)-26.22as on Dec 31, 2024
-
Total Equity Funding
$24.4 M (USD)
in 4 rounds
-
Latest Funding Round
$751.37 K (USD), Series B
Mar 04, 2024
-
Investors
Shinhan Bank
& 11 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of NEUROPHET
NEUROPHET is a publicly listed company on the KRX with ticker symbol 380550 in South Korea, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of NEUROPHET
NEUROPHET has successfully raised a total of $24.4M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $751.37 thousand completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $751,371
-
First Round
First Round
(26 Nov 2019)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2024 | Amount | Series B - NEUROPHET | Valuation | Samjin Pharm |
|
| Nov, 2021 | Amount | Series B - NEUROPHET | Valuation | SBI Investment Korea , Kolon Investments |
|
| Jan, 2020 | Amount | Series A - NEUROPHET | Valuation | SBI Investment Korea |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in NEUROPHET
NEUROPHET has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Shinhan Bank, SBI Investment Korea and Samjin Pharm. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sector-agnostic VC firm investing in geographies such as South Korea
|
Founded Year | Domain | Location | |
|
Venture capital and private equity are invested in various sectors.
|
Founded Year | Domain | Location | |
|
Private equity investments in South Korea are managed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by NEUROPHET
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - NEUROPHET
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Neurophet Comparisons
Competitors of NEUROPHET
NEUROPHET operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Viz.ai, icometrix, RapidAI, Jvion and BrainSightAI, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
AI and cloud-powered software for stroke care coordination is developed.
|
|
| domain | founded_year | HQ Location |
AI-based software for brain MRI analysis is provided by icometrix.
|
|
| domain | founded_year | HQ Location |
Provider of AI-based neuroimaging software for physicians
|
|
| domain | founded_year | HQ Location |
Deep learning-based illness prediction solutions are provided by Jvion.
|
|
| domain | founded_year | HQ Location |
Functional brain mapping is enabled by AI-driven connectomics platform.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Neurophet
Frequently Asked Questions about NEUROPHET
When was NEUROPHET founded?
NEUROPHET was founded in 2016 and raised its 1st funding round 3 years after it was founded.
Where is NEUROPHET located?
NEUROPHET is headquartered in Seoul, South Korea.
Who is the current CEO of NEUROPHET?
Donghyeon Kim is the current CEO of NEUROPHET. They have also founded this company.
Is NEUROPHET a funded company?
NEUROPHET is a funded company, having raised a total of $24.4M across 4 funding rounds to date. The company's 1st funding round was a Series A of $2.54M, raised on Nov 26, 2019.
What is the annual revenue of NEUROPHET?
Annual revenue of NEUROPHET is $1.51M as on Dec 31, 2024.
What does NEUROPHET do?
NEUROPHET was founded in 2016 in Seoul, South Korea, within the neuro-engineering sector. AI-based simulation software is provided for doctors and researchers focused on electrical brain stimulation. Individual 3D brain models are generated automatically from MRI scans for each patient. Effects of stimulation under various treatment parameters are simulated and analyzed in clinical environments to support medical decision-making.
Who are the top competitors of NEUROPHET?
NEUROPHET's top competitors include Viz.ai, BrainSightAI and RapidAI.
Is NEUROPHET publicly traded?
Yes, NEUROPHET is publicly traded on KRX under the ticker symbol 380550.
Who are NEUROPHET's investors?
NEUROPHET has 12 investors. Key investors include Shinhan Bank, SBI Investment Korea, Samjin Pharm, Future Play, and Kolon Investments.
What is NEUROPHET's ticker symbol?
The ticker symbol of NEUROPHET is 380550 on KRX.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.